Antitumor activity of IMC-038525, a novel oral tubulin polymerization inhibitor

Translational Oncology

Volumn 3, Issue 5, 2010, Pages 318-325

  Tuma, Maria Carolina ^h   Malikzay, Asra ^a   Ouyang, Xiaohu ^b   Surguladze, David ^h   Fleming, James ^c   Mitelman, Stan ^a   Camara, Margarita ^d   Finnerty, Bridget ^e   Doody, Jacqueline ^h   Chekler, Eugene L P ^f   Kussie, Paul ^g   Tonra, James R ^h  

^a MERCK RESEARCH LABORATORIES   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NEVADA   (United States)

^d MEDIMMUNE   (United States)

^e Medsite Inc   (United States)

^f PFIZER INC   (United States)

^g Aggamin Biologics   (United States)

^h ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

( 2,3 DIHYDROBENZO[ 1,4 ]DIOXIN 6 YL)( 5 ( 2 [(PYRIDIN 4 YLMETHYL)AMINO]PHENYL)[ 1,3,4 ]OXADIAZOL 2 YL)AMINE; COLCHICINE; IMC 038525; OXADIAZOLE DERIVATIVE; PACLITAXEL; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; BREAST TUMOR; CELL CYCLE ARREST; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MELANOMA; MICROTUBULE ASSEMBLY; MITOSIS; MOUSE; MYELINATION; NEUROTOXICITY; NEUTROPHIL COUNT; NONHUMAN; SCIATIC NERVE; SQUAMOUS CELL CARCINOMA; STRUCTURE ACTIVITY RELATION; TUMOR CELL; TUMOR GROWTH; TUMOR XENOGRAFT;

EID: 78449245986     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.10160     Document Type: Article

References (30)

1. Jordan MA and Wilson L (2004). Microtubules as a target for anticancer drugs. Nat Rev Cancer 4, 253-265.
2. Pasquier E and Kavallaris M (2008). Microtubules: a dynamic target in cancertherapy. IUBMB Life 60, 165-170.
3. Ferlini C, Gallo D, and Scambia G (2008). New taxanes in development. Expert Opin Investig Drugs 17, 335-347.
4. Duflos A, Kruczynski A, and Barret JM (2002). Novel aspects of natural andmodified Vinca alkaloids. Curr Med Chem Anticancer Agents 2, 55-70.
5. Fojo Tand Menefee M (2007). Mechanisms of multidrug resistance: the potentialrole of microtubule-stabilizing agents. Ann Oncol 18(suppl 5), v3-v8.
6. Orr GA, Verdier-Pinard P, McDaid H, and Horwitz SB (2003). Mechanisms oftaxol resistance related to microtubules. Oncogene 22, 7280-7295.
7. Carlson RO (2008). New tubulin targeting agents currently in clinical development. Expert Opin Investig Drugs 17, 707-722.
8. Attard G, Greystoke A, Kaye S, and De Bono J (2006). Update on tubulinbindingagents. Pathol Biol (Paris) 54, 72-84.
9. Bennouna J, Delord JP, Campone M, and Nguyen L (2008). Vinflunine: a newmicrotubule inhibitor agent. Clin Cancer Res 14, 1625-1632.
10. Donovan D and Vahdat LT (2008). Epothilones: clinical update and future directions. Oncology (Williston Park) 22, 408-416.
11. Lee JJ and Swain SM (2008). The epothilones: translating from the laboratoryto the clinic. Clin Cancer Res 14, 1618-1624.
12. Goodin S (2008). Novel cytotoxic agents: epothilones. Am J Health Syst Pharm 65, S10-S15.
13. Ouyang X, Chen X, Piatnitski EL, Kiselyov AS, He HY, Mao Y, Pattaropong V, Yu Y, Kim RH, Kincaid J, et al. (2005). Synthesis and structure-activity relationshipsof 1,2,4-triazoles as a novel class of potent tubulin polymerization inhibitors. Bioorg Med Chem Lett 15, 5154-5159.
14. Ouyang X, Piatnitski EL, Pattaropong V, Chen X, He HY, Kiselyov AS, Velankar A, Kawakami J, Labelle M, Smith L 2nd, et al. (2006). Oxadiazole derivatives as anovel class of antimitotic agents: synthesis, inhibition of tubulin polymerization, and activity in tumor cell lines. Bioorg Med Chem Lett 16, 1191-1196.
15. Pettit GR, Singh SB, Hamel E, Lin CM, Alberts DS, and Garcia-Kendall D (1989). Isolation and structure of the strong cell growth and tubulin inhibitorcombretastatin A-4. Experientia 45, 209-211.
16. Scudiero DA, Monks A, and Sausville EA (1998). Cell line designation change:multidrug-resistant cell line in the NCI anticancer screen. J Natl Cancer Inst 90, 862.
17. Tahir SK, Kovar P, Rosenberg SH, and Ng SC (2000). Rapid colchicinecompetition-binding scintillation proximity assay using biotin-labeled tubulin. Biotechniques 29, 156-160.
18. Lacroix M (2008). MDA-MB-435 cells are from melanoma, not from breastcancer. Cancer Chemother Pharmacol 63(3), 567.
19. Mimura Y, Kato H, Eguchi K, and Ogawa T (2000). Schedule dependency ofpaclitaxel-induced neuropathy in mice: a morphological study. Neurotoxicology 21,513-520.
20. McGrogan BT, Gilmartin B, Carney DN, and McCann A (2008). Taxanes, microtubulesand chemoresistant breast cancer. Biochim Biophys Acta 1785, 96-132.
21. Rowinsky EK (2002). Taxane analogues: distinguishing royal robes from the"emperor's new clothes". Clin Cancer Res 8, 2759-2763.
22. Gianni L, Kearns CM, Giani A, Capri G, Viganó L, Lacatelli A, Bonadonna G, and Egorin MJ (1995). Nonlinear pharmacokinetics and metabolism of paclitaxel andits pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 13,180-190.
23. Rowinsky EK and Calvo E (2006). Novel agents that target tublin and relatedelements. Semin Oncol 33, 421-435.
24. Wolf S, Barton D, Kottschade L, Grothey A, and Loprinzi C (2008). Chemotherapyinducedperipheral neuropathy: prevention and treatment strategies. Eur J Cancer 44, 1507-1515.
25. Swain SM and Arezzo JC (2008). Neuropathy associated with microtubule inhibitors:diagnosis, incidence, and management. Clin Adv Hematol Oncol 6, 455-467.
26. Bacher G, Nickel B, Emig P, Vanhoefer U, Seeber S, Shandra A, Klenner T, and Beckers T (2001). D-24851, a novel synthetic microtubule inhibitor, exerts curativeantitumoral activity in vivo, shows efficacy toward multidrug-resistant tumorcells, and lacks neurotoxicity. Cancer Res 61, 392-399.
27. Aneja R, Lopus M, Zhou J, Vangapandu SN, Ghaleb A, Yao J, Nettles JH, Zhou B, Gupta M, Panda D, et al. (2006). Rational design of the microtubuletargetinganti-breast cancer drug EM015. Cancer Res 66, 3782-3791.
28. Gale RP (1985). Antineoplastic chemotherapy myelosuppression: mechanisms andnew approaches. Exp Hematol 13(suppl 16), 3-7.
29. Scripture CD, Figg WD, and Sparreboom A (2006). Peripheral neuropathy inducedby paclitaxel: recent insights and future perspectives. Curr Neuropharmacol 4, 165-172.
30. Kasibhatla S, Baichwal V, Cai SX, Roth B, Skvortsova I, Skvortsov S, Lukas P, English NM, Sirisoma N, Drewe J, et al. (2007). MPC-6827: a small-moleculeinhibitor of microtubule formation that is not a substrate for multidrug resistancepumps. Cancer Res 67, 5865-5871.